<DOC>
	<DOCNO>NCT00003702</DOCNO>
	<brief_summary>Randomized phase III trial compare effectiveness methotrexate dactinomycin treat patient gestational trophoblastic neoplasia . Drugs use chemotherapy use different way stop tumor cell divide stop grow die . It yet know whether methotrexate effective dactinomycin treat patient gestational trophoblastic neoplasia .</brief_summary>
	<brief_title>Methotrexate Compared With Dactinomycin Treating Patients With Gestational Trophoblastic Neoplasia</brief_title>
	<detailed_description>OBJECTIVES : I . Compare efficacy methotrexate v dactinomycin , measure complete response rate , patient low-risk gestational trophoblastic neoplasia . II . Compare toxicity regimens patient . III . Determine whether definition persistent gestational trophoblastic neoplasia accurate ( determine likelihood beta human chorionic gonadotropin [ HCG ] titer would decline day treatment initiate ) . OUTLINE : This randomize study . Patients randomize 1 2 treatment arm . ARM I : Patients receive methotrexate intramuscularly weekly absence disease progression unacceptable toxicity . ARM II : Patients receive dactinomycin IV 15 minute every 2 week absence disease progression unacceptable toxicity . All patient continue treatment 1 beta human chorionic gonadotropin ( HCG ) titer institutional normal . Patients receive 1 additional consolidation treatment . Patients follow every 4 week 1 year .</detailed_description>
	<mesh_term>Choriocarcinoma</mesh_term>
	<mesh_term>Trophoblastic Neoplasms</mesh_term>
	<mesh_term>Gestational Trophoblastic Disease</mesh_term>
	<mesh_term>Hydatidiform Mole</mesh_term>
	<mesh_term>Methotrexate</mesh_term>
	<mesh_term>Dactinomycin</mesh_term>
	<criteria>Histologically proven lowrisk gestational trophoblastic neoplasia ( persistent hydatidiform mole choriocarcinoma ) , define 1 follow : Less 10 % decrease beta human chorionic gonadotropin ( HCG ) titer 3 weekly titer Greater 20 % sustain rise beta HCG titer two consecutive week Persistently elevate beta HCG titer 4 month initial curettage ( great 5 mIU/mL minimum ) Histologically prove nonmetastatic choriocarcinoma Metastases vagina , parametria , lung ( single pulmonary lesion great 2 cm ) WHO score 06 ( include blood group CT lung ) No histologically confirm placental site pseudotumor Must undergone least 1 uterine curettage Previously untreated disease Performance status GOG 02 WBC least 3,000/mm^3 Granulocyte count least 1,500/mm^3 Platelet count least 100,000/mm^3 Bilirubin great 1.5 time upper limit normal ( ULN ) SGPT SGOT great 3 time ULN Alkaline phosphatase great 3 time ULN No significant prior abnormal hepatic function Creatinine great 2.0 mg/dL No significant prior abnormal renal function Not pregnant nursing Fertile patient must use effective contraception one year study entry No prior concurrent malignancy within past 5 year except nonmelanomatous skin cancer No prior chemotherapy gestational trophoblastic neoplasia No concurrent curettage except need control vaginal bleeding rule placental site pseudotumor</criteria>
	<gender>Female</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2016</verification_date>
</DOC>